Fresenius Kabi in the news

Multiple biosimilar manufacturers, including Fresenius Kabi, are engaged in patent disputes against Millennium's Entyvio in the UK, France, and the Netherlands to clear the path for their generic versions.

Fresenius Kabi and AABB announced the 21st annual Blood Collectors Week to honor blood collection professionals for their life-saving work.

Fresenius Kabi launched a generic Sugammadex injection in the US, impacting Fresenius' stock performance and outlook.

Fresenius Medical Care received an FDA warning for cGMP violations at its Utah facility due to leaking sterile peritoneal dialysis solution bags and insufficient quality control, following a separate recall by Fresenius Kabi.

Fresenius stock is stable in the mid-40 EUR range, driven by strong Q2 2026 growth and the launch of a new generic drug by Fresenius Kabi in the US.

Fresenius Kabi launched generic Sugammadex in prefilled syringes in the U.S. to enhance medication management in operating rooms.

Fresenius Medical Care's Utah plant received an FDA warning letter for manufacturing deficiencies, including failure to investigate customer complaints and inadequate inspection protocols, risking patient safety.

Despite its defensive profile and growth in clinical nutrition, Fresenius's stock is underperforming compared to US healthcare peers, experiencing recent declines and market skepticism.

Fresenius stock shows robust development in late summer 2026, driven by strong Q2 2026 results, especially growth in Fresenius Kabi and stable profitability at Helios.

Fresenius sold FMC shares to reduce debt and saw strong performance from Fresenius Kabi, leading to an upgraded financial outlook and positive analyst ratings.

Fresenius's stock dipped following the sale of FMC shares, aiming to reduce debt and invest in growth, while Fresenius Kabi remains a key revenue driver.

Fresenius raised its 2026 profit outlook and reported strong Q2 results, driven by its Kabi and Helios segments, while launching a new venture capital fund.

Fresenius improved Q2 performance and raised its profit outlook, with 2027 prospects relying on Kabi's growth products, Helios's margins, and enhanced cash flow amid market risks.

Fresenius recently converted its shares, received rating upgrades, and raised its earnings guidance, despite a product recall from its Kabi division.

Fresenius is converting share types, received positive analyst and rating agency outlooks, and its subsidiary Fresenius Kabi recalled a drug batch due to glass particles, all while maintaining a strong financial forecast.

UBS increased Fresenius' price target to 56 euros, maintaining a buy rating, citing strong performance from its Kabi division and reduced concerns about Helios, alongside a positive outlook upgrade from Fitch.

Fresenius received multiple positive updates, including a "Buy" rating confirmation, a switch to registered shares, and an upgraded credit outlook from Fitch, driven by strong performance and strategic focus on its core businesses.

UBS increased Fresenius's stock price target to 56 Euros, citing Kabi's growth and improved outlook for Helios, with other banks and Fitch also confirming positive assessments.

Fresenius's stock price and credit rating have risen following structural simplification, debt reduction, and strong performance in its Kabi and Helios segments, alongside a promising biosimilar pipeline.

Fresenius is undergoing a corporate transformation, converting to registered shares, receiving an upgraded credit outlook from Fitch due to debt reduction, and seeing strong growth from Fresenius Kabi and Helios, leading to an increased annual forecast.